Biotech company, Artelo Biosciences, announces plans for a public offering of securities which will be underwritten.
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on developing treatments for various conditions, including cancer, pain, dermatologic, and neurological conditions, has announced a public offering of its common stock and/or pre-funded warrants.
The offering is being made through a "shelf" registration statement on Form S-3, which was filed with the U.S. Securities and Exchange Commission (SEC) and declared effective on July 14, 2023. The terms of the offering will be described in a prospectus supplement, which will form a part of the effective registration statement.
R.F. Lafferty & Co., Inc. is the sole book-running manager for the offering. The shares of common stock and/or pre-funded warrants are being offered by Artelo Biosciences, Inc. itself.
Artelo Biosciences is conducting clinical-stage research focused on anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. The company's management team includes experienced executives and world-class researchers, working diligently to advance their research.
Prospective investors are cautioned not to place undue reliance on forward-looking statements. Artelo Biosciences' forward-looking statements are based on current expectations and involve known and unknown risks. The company's filings with the Securities and Exchange Commission outline potential risks.
The offering is subject to market conditions, and there is no assurance as to when or if it will be completed. Prospective investors are advised to carefully review the prospectus supplement and accompanying prospectus, which can be obtained from the SEC's website or R.F. Lafferty & Co., Inc.
Artelo Biosciences' investor relations contact is Crescendo Communications, LLC. For inquiries, contact Tel: 212-671-1020 or Email: [email protected].
The company has also disclosed that it has a digital asset treasury strategy, deploying excess capital into Solana.
Artelo Biosciences' press release does not constitute an offer to sell or solicit an offer to buy securities, nor will there be any sale of securities until registered or qualified under securities laws.
Read also:
- Understanding Hemorrhagic Gastroenteritis: Key Facts
- Stopping Osteoporosis Treatment: Timeline Considerations
- Trump's Policies: Tariffs, AI, Surveillance, and Possible Martial Law
- Expanded Community Health Involvement by CK Birla Hospitals, Jaipur, Maintained Through Consistent Outreach Programs Across Rajasthan
